Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

By K. Cusi. Gastroenterology, 2012

885 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/a05bac4cc82492e2057a0b7f5451d10804236034

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Physiology

Citations in the corpus

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, neutral): “019 Total body fat by DXA, % 36 (8) 36 (7) 2 (1 to 3) <0.”
Intestinal permeability – a new target for disease prevention and therapy (2014, background): “The altered intestinal barrier and the subsequent translocation of small amounts of bacteria or bacterial products is now regarded as one important mechanism causing the low-grade inflammation characteristic for metabolic diseases possibly linked to the subsequent infiltration of organs such as live”
Non Alcoholic Fatty Liver Disease, Hepatic Insulin Resistance and Type 2 Diabetes (2014, background): “Ectopic accumulation of hepatic lipids has clearly been linked to the development of hepatic insulin resistance and type 2 diabetes.(5,6) The present review will focus on the physiological and cellular mechanisms that lead to NAFLD as well as the cellular and molecular mechanisms for lipidinduced he”
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice (2017, background): “levels in obese foz/foz mice, all of which contribute mechanistically to NASH [1,2,5-7].”
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review (2023, background): “Also, it is important to remember that age and obesity are highly associated with NAFLD prevalence[31] and these factors may differ according to the region of the world.”
Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. (2015, neutral): “NASH Patients Show Systemic Inflammation but Not Systemic Oxidative Stress Circulating adipocytokines may also play a role in the pathogenesis of NAFLD (Cusi, 2012).”
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “The ability of thiazolidinediones to reverse adipose tissue dysfunction and insulin resistance in obesity and T2DM have led to randomized controlled trials (RCTs) exploring their role in NASH (160).”